Epstein-Barr Virus-Associated Membrane-Reactive Antibodies During Long Term Survival After Burkitt's Lymphoma
AUTOR(ES)
Gunvén, Peter
RESUMO
Antibodies to Epstein-Barr virus associated cell membrane antigens persisted or slowly decreased during prolonged uncomplicated survival of patients with Burkitt's lymphoma in remission. Serum was sampled from four patients within 6 months before recurrence occurring after the first year and preceded by remission during more than 6 months. Rapid and significant decreases of the antibodies before clinical recognition of the recurrences were found in three patients. The fourth patient had slowly increasing titers before relapse. Immune stimulant treatment during remission, with BCG (Bacille Calmette Guérin vaccine) or BCG + Bordetella pertussis, temporarily increased the antibody levels. Possible mechanisms for the observed titer changes before recurrence are discussed.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=388241Documentos Relacionados
- Epstein-Barr virus-associated thymidine kinase.
- Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome.
- Immune regulation in Epstein-Barr virus-associated diseases.
- Epstein-Barr virus provides a survival factor to Burkitt's lymphomas
- Antibodies against synthetic peptides react with the second Epstein-Barr virus-associated nuclear antigen.
